Equillium (FRA:0FY) ROE % Adjusted to Book Value : -0.10% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Equillium ROE % Adjusted to Book Value?

Equillium's ROE % for the quarter that ended in Sep. 2024 was -0.12%. Equillium's PB Ratio for the quarter that ended in Sep. 2024 was 1.22. Equillium's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -0.10%.

Equillium ROE % Adjusted to Book Value Historical Data

The historical data trend for Equillium's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium ROE % Adjusted to Book Value Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-29.66

-34.14

-33.21

-143.93

-48.58

Equillium Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-55.76	-40.10	-14.29	8.32	-0.10

Competitive Comparison of Equillium's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Equillium's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Equillium's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Equillium's ROE % Adjusted to Book Value falls into.

Equillium ROE % Adjusted to Book Value Calculation

Equillium's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-48.09%	/	0.99
	=	-48.58%

Equillium's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-0.12%	/	1.22
	=	-0.10%

Equillium ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Equillium's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

EQ:USA 0A4D:UK 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium Headlines

No Headlines